Live Marvell Technology Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow Theriva Biologics, Inc.

Get SEC filing alerts via email and in your feed for Theriva Biologics, Inc.

TOVX

Theriva Biologics, Inc.

About Theriva Biologics, Inc.

Theriva Biologics is a clinical-stage biotech developing cancer therapeutics, notably oncolytic viruses like VCN-01 for solid tumors and pancreatic cancer. Its platform leverages virus-induced tumor cell destruction and immune activation, with potential for intravenous delivery. The company also explores microbiome-focused therapies for infections like C. difficile and VRE, aiming to address high unmet medical needs in oncology and infectious diseases.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from Theriva Biologics, Inc.

1
1
Theriva Biologics, Inc. Theriva Biologics Reports Q1 2026 Financial Results with Improved Loss and First Revenue Generation

Via official filing (AI summary) | about 1 month ago | 0 comments

2
1
Theriva Biologics, Inc. Theriva Biologics Reports $23.7 Million Net Loss and Strategic License Agreement with Rasayana Therapeutics

Via official filing (AI summary) | 3 months ago | 0 comments

3
1
Theriva Biologics, Inc. Theriva Biologics Reports $4.4 Million Net Loss, Focuses on Oncology Pipeline

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
Theriva Biologics, Inc. Theriva Biologics Reports $13.1 Million Net Loss for Q2 2025 Amid Rising Expenses

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
Theriva Biologics, Inc. Theriva Biologics Reports $4.3 Million Net Loss, Focuses on Oncology Pipeline

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
Theriva Biologics, Inc. Theriva Biologics Reports $25.7 Million Net Loss for Fiscal Year 2024

Via official filing (AI summary) | over 1 year ago | 0 comments

7
1
Theriva Biologics, Inc. Theriva Biologics Reports Significant Financial Challenges, Net Loss of $7.7M in Latest Quarter

Via official filing (AI summary) | over 1 year ago | 0 comments